MassChallenge

Extracellular specializes in accelerating biotechnology advancements by applying its expertise in extracellular channels biology, digitalization, and biomanufacturing. The company leverages its deep insights into cellular behavior and scale-up experience to efficiently produce biomass for cultivated meat companies. It achieves this by digitalizing process development, enabling data-driven decision-making at scale. Additionally, Extracellular offers an R&D platform and biomanufacturing solutions tailored for sustainable biotech sectors such as cultivated meat, plant cell culture, bio-cosmetics, supplements, and materials. Its focus is on reducing R&D costs and timeframes to facilitate the swift market entry of sustainable biotech companies.

Embryoxite is a biotechnology company specializing in non-invasive diagnostic services for pre-implantation embryos in human-assisted reproduction. It operates a platform that combines artificial intelligence, metabolomics, embryo imaging, and clinical data to enhance embryo selection accuracy and improve patient outcomes for fertility clinics and reproductive specialists.

SCALE Advanced Biocomposites specializes in the development and manufacturing of bio-based materials, focusing on natural-fiber composites. The company aims to enhance performance while reducing costs and greenhouse gas emissions, contributing to the decarbonization of various industries, including sporting goods, automotive, wind power, and aerospace. SCALE's innovative materials and technologies are designed to fully or partially replace carbon fiber, making them a sustainable alternative that meets the demands of high-performance applications. By accelerating the adoption of bio-based materials, SCALE plays a crucial role in transforming the built environment towards lower emissions and greater sustainability.

Nature's Principles is a pioneering company that originated from a Ph.D. project at the Delft University of Technology in the Netherlands. The company has developed a patented mixed culture fermentation technology that aims to revolutionize traditional agro-chemical production methods. This innovative process utilizes principles derived from nature to cultivate microorganisms, enhancing their productivity without the need for genetic engineering. By transforming low-value waste streams such as sugar beet, pulp, and molasses into valuable products like lactic acid and poly-lactic acid for bioplastics, Nature's Principles enables clients to reduce reliance on oil-based chemicals. The technology not only improves efficiency but also demonstrates significant advantages in terms of water usage, carbon dioxide emissions, and land utilization compared to conventional alternatives.

BioMixing is a biotechnology company dedicated to enhancing bio-fermentation processes. It specializes in developing innovative agitation systems for bioreactors, leveraging fluid dynamics principles to minimize cell damage and optimize mixing within the vessel. This enables other organizations to improve the efficiency of their fermenters and bioreactors, thereby addressing various biotechnological challenges.

Cellorama multipurpose devices, reagents, and processes are patent-pending and protect cell structure and integrity during many procedures. User-friendly and cost-effective devices are designed to minimize stressful stages in the laboratory while saving time and vital resources.

Symphony Biosciences is a biotechnology company dedicated to developing innovative cancer treatments that target solid tumors, with a primary focus on triple-negative breast cancer. Recognizing the limitations of existing therapies, which often involve toxic chemotherapies with poor survival rates, Symphony Biosciences aims to orchestrate the immune response to improve outcomes for patients. The company's research emphasizes the use of biomaterials to enhance cancer treatment options, providing healthcare professionals with effective tools to combat challenging cancer types. Through its focused efforts, Symphony Biosciences strives to advance the field of oncology and improve the quality of care for patients facing solid tumors.

Trove Health is a company that offers a clinical trial recruitment platform designed to facilitate access to patient data for patients, healthcare providers, and life sciences organizations. The platform creates a diverse and consented database of prospective trial participants, enabling researchers to efficiently identify and recruit patients who meet specific enrollment criteria across various geographies and therapeutic areas. By doing so, Trove Health supports the advancement of medical research while empowering patients to manage their own health data, including the potential to monetize it and receive personalized treatment options.

Dart Biosciences works in the healthcare industry. It creates tailored gene therapies for a variety of uncommon and prevalent disorders.

Stellate Therapeutics is a private biotechnology company that specializes in the development of small molecules derived from human gut bacteria, aimed at creating personalized therapies for neurological diseases. The company focuses on researching the gut-brain axis and its implications for age-related neurological conditions. Stellate has established a robust portfolio of drug candidates, including AMA-101, which is positioned as a potential first-in-class therapy for Parkinson's disease. Through its innovative microbiome-derived medicine platform, Stellate Therapeutics engages in various stages of drug development, including discovery, screening, production, and diagnostic development, with the goal of providing effective treatments for patients suffering from neurological disorders.

Arnav Biotech is a biotechnology company that operates as a Contract Development and Manufacturing Organization (CDMO), specializing in mRNA technology. It offers services for the design, development, and manufacturing of custom and cataloged mRNA products, supporting research, therapeutics, and vaccines. By providing these services, Arnav Biotech enables researchers to concentrate on their specific areas of interest, thereby democratizing access to mRNA-based life sciences.

Speratum is a biopharmaceutical company focused on microRNA-directed oncology therapies. The Company was founded in 2014 by Christian Marín-Müller, Ph.D. and is dedicated to the development of a patented treatment for pancreatic cancer based on the combination of tumor suppressive microRNA molecules and nanoparticle-based drug delivery technologies. The Company is currently entering the final stage of preclinical trials for the pancreatic cancer therapy, while simultaneously expanding the patent’s coverage to incorporate other types of cancer and non-cancer indications and illnesses and expanding its intellectual property (IP) portfolio with complementary technologies in the fields of nanotechnology, medical devices and veterinary medicine.

Nanoplex is a healthcare and life sciences company.

ZiO Health is a biotechnology company focused on enhancing patient outcomes through its innovative pocket-sized laboratory testing technology. The company has developed proprietary biosensor devices that utilize machine learning algorithms to provide real-time results tailored to individual patient profiles. These multi-functional electronic devices are designed for measuring, testing, and detecting the molecular composition of various chemical and biological substances, enabling users to assess the presence, absence, or quantity of specific target molecules. By delivering quality home diagnostics and personalized testing solutions, ZiO Health aims to empower individuals to optimize their health and prevent illness.

Skygenic is an innovative infrastructure and data analysis platform designed to facilitate the research process for scientists working with biological data. Developed in collaboration with physician scientists from Harvard Medical School and Boston Children's Hospital, the platform addresses challenges faced in early-stage and translational research by enabling non-programming scientists to conduct their own data analyses. By streamlining the storage, transfer, and interpretation of genomic data, Skygenic reduces the reliance on bioinformaticians, thereby accelerating discovery within academic institutions, hospitals, biotechnology, and pharmaceutical organizations. This approach allows for more efficient research efforts at a lower cost and in a shorter timeframe.

YouthBio Therapeutics Inc. is a biotechnology company specializing in the development of rejuvenation gene therapies through partial reprogramming techniques inspired by Yamanaka factors. The company aims to harness cellular reprogramming to restore youthful gene expression profiles in targeted cells, which can lead to beneficial therapeutic effects in corresponding organs. By focusing on these innovative approaches, YouthBio Therapeutics seeks to empower patients to prevent age-related diseases and potentially delay or reverse the aging process.

Narval is a biotechnology company specializing in the development of synthetic antibody mimetic proteins (AMPs). These AMPs are significantly smaller than conventional antibodies, yet retain their biological functionality. They offer several advantages, including the ability to penetrate tissue barriers, generate limited immune reactions, target small and hard-to-reach antigens, and withstand heat. This technology enables Narval to create novel first-in-class immunotherapeutics for diseases previously challenging to treat using monoclonal antibodies. Their focus includes respiratory, eye, and autoimmune diseases, with delivery methods such as inhaled antibodies, eye drops, and transdermal patches. Narval leverages machine learning and artificial intelligence to optimize its drug development capabilities.

Azul Bio specializes in marine ecosystem preservation and enhancement, focusing on coral reef restoration. They employ advanced biological analysis services to monitor and maintain aquatic environments, offering DNA-based biodiversity assessments, species genotyping, microbiome profiling, and disease detection. This data empowers marine researchers and industries to improve aquaculture practices and safeguard ocean ecosystems against climate change.

Azooka is a biotechnology company specializing in the production of proprietary fluorophores, which are used as molecular biology tools in life science research and diagnostic applications. Their product portfolio includes fluorescent dyes for DNA, RNA, chromosomes, live cells, and molecular-grade sample collection mediums. Azooka's mission is to provide secure, sustainable, and affordable biotech consumables globally, with a focus on accessibility for all nations. Notably, the company has been recognized as the "Best Women-Led Enterprise."

Anviron is an advanced therapeutic company focused on developing innovative treatments for late-stage cancers. The organization is committed to addressing unmet medical needs in oncology through its platform, which is grounded in cutting-edge scientific research. Anviron's team comprises scientists, doctors, and clinicians who collaborate to create therapies aimed at improving patient outcomes and transforming cancer care. By leveraging their collective expertise, the company seeks to make significant advancements in the fight against difficult-to-treat cancers.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

BioBQ is a cultivated meat company focused on producing slaughter-free beef brisket and other barbecue meats from cultured animal cells. Utilizing proprietary technologies, BioBQ can efficiently create whole cuts of meat in a matter of weeks, significantly reducing the time required compared to traditional cattle farming. This innovative process not only allows for precise control over meat content and flavor but also minimizes the environmental impact typically associated with conventional meat production. By offering a sustainable alternative, BioBQ aims to meet consumer demand for tasty and ethically produced barbecue options, ensuring that meat can be enjoyed without adverse effects on the climate, environment, or animal welfare.

MyoGene Bio is a biotechnology company focused on developing innovative therapies for muscle diseases, with an initial emphasis on gene-editing treatments for Duchenne muscular dystrophy. The company employs advanced technologies to address the underlying causes of this condition, aiming to significantly improve disease progression and outcomes for patients. By targeting the root of the disorder, MyoGene Bio seeks to provide clinicians and patients with effective solutions that have a meaningful impact on the management of devastating muscle disorders.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

Selmod, located in Basel, Switzerland, specializes in the development of innovative small molecule therapies aimed at treating life-threatening, multi-drug resistant infections. The company is committed to discovering and advancing first-in-class drug candidates that provide second-line and last-resort treatment options for patients in hospital settings, particularly where conventional therapies have failed due to resistance. Selmod's approach includes the development of antibiotics with dual modes of action to effectively counteract existing resistance mechanisms. Its leading candidates, SLM500, SLM100, and SLM300, have demonstrated success in preclinical animal studies and are positioned within a promising market projected to exceed $9 billion. The company aims to capture a substantial market share shortly after entry, supported by a leadership team with extensive experience in clinical development for major pharmaceutical firms. Funding will be utilized to advance SLM500 through IND-enabling studies and to optimize additional lead candidates for further development.

Ronawk is a biotechnology company specializing in the development of T-Block technology that produces patient-specific biologics for the treatment of various diseases, including cancer, organ injuries, and burns. The company's proprietary method allows for the growth of primary stem cells in a three-dimensional environment, preserving the essential characteristics of these cells outside the human body. This innovative approach enables the rapid expansion of stem cells, facilitating their use in early-stage diagnostics and the repair of damaged tissues. Ronawk's technology not only enhances the efficiency of growing human cells but also supports tissue generation and disease modeling, making significant contributions to the fields of regenerative medicine and reconstructive surgery.

LIALT Laboratorio de Investigación Alternativa develops toxicological evaluations without the use of animals. LIALT replaces the use of animals through the use of three-dimensional tissues in conjunction with internationally recognized protocols that provide more specific information on the mechanisms of toxic action than that obtained in animals, offering a solution to the problem previously exposed.

Stemloop is a biosensor company dedicated to harnessing biological technology to meet global challenges in chemical sensing and detection. The company focuses on developing innovative, cell-free biosensing products that simplify and enhance the testing process for chemical and molecular analysis. By utilizing genetically encoded sensing mechanisms, Stemloop aims to provide accurate and scalable solutions that are both cost-effective and accessible. This approach allows medical professionals to obtain faster and more reliable test results, ultimately improving healthcare outcomes while addressing unmet needs in laboratory testing. Through its novel technology, Stemloop seeks to revolutionize the landscape of biosensing and contribute meaningfully to various sectors.

Leucine Rich Bio is a pioneering genomics-based company in India, focused exclusively on the human microbiome, often referred to as the "Second Genome." By leveraging advanced genomic techniques, the company aims to address crucial uncertainties in precision medicine related to the microbiome's impact on health and wellness. Leucine Rich Bio offers a unique platform that provides customized nutritional recommendations and personalized supplements tailored to an individual's intestinal microflora. Its applications span various medical fields, including gastroenterology, endocrinology, oncology, mental health, and reproductive health, enabling clients to achieve clinical resolutions and improve overall well-being. The company is dedicated to advancing understanding and utilization of microbiome research for better health outcomes.

Michroma Corporation is a biotechnology company that specializes in producing natural thermostable colorants derived from filamentous fungi for the food and cosmetics industries. Founded in 2019, the company operates from locations in San Francisco, California, and Rosario, Argentina. By leveraging synthetic biology, Michroma develops proprietary fungal strains that can be cultivated in bioreactors, allowing for the sustainable and cost-effective production of high-performance ingredients. Its initial offerings focus on pH-stable and heat-stable colorants, which are designed to replace synthetic pigments and those sourced from animals and plants. In addition to colorants, Michroma is also engaged in the production of mycoprotein and other innovative ingredients, collaborating with leading companies in the food and beverage and cosmetic sectors.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

BestHealth4U is a company focused on researching and developing advanced medical adhesive technologies aimed at enhancing patient health and safety. The company offers innovative, eco-friendly adhesive solutions that prevent skin injuries, accelerate healing, and improve overall patient well-being. By transforming the attachment methods of bandages, dressings, and medical devices, BestHealth4U addresses common issues such as skin damage, pain, irritation, and infection caused by traditional medical adhesives. Its commitment to creating safe and effective products positions the company as a leader in the medical device industry, particularly in the realm of class 1 medical devices.

BioEclosion is a biotechnology company specializing in the development of user-friendly, rapid diagnostic tools. Its core technology, Celifast, is a non-invasive method for detecting celiac disease, validated and patented. The company aims to expand this platform to other emerging diseases, using molecular biomarkers for swift identification. BioEclosion's device comprises a single-use cartridge tailored to each application and a portable, battery-operated reader, making it versatile for human and veterinary health, as well as food and environmental safety.

TissueLabs is the platform for creating organs and tissues in the lab. We offer biomaterials, equipment, and services to support tissue engineering and regenerative medicine. Our products are created to allow performing state-of-the-art research, from drug discovery to organ fabrication. Currently, we are focused on attending the academic life sciences market. In the future, our mission is to fabricate lab-grown tissues and organs, for both research and therapeutic applications.

React4life is an Italian biotech company established in 2016 by Silvia Scaglione and Maurizio Aiello, following over 15 years of research and development. The company focuses on advancing biomedical research through its innovative MIVO® (Multi In Vitro Organ) technology, which represents the next generation of organ-on-a-chip systems. This microphysiological platform allows scientists to replicate human biology in the laboratory more accurately, addressing the limitations of traditional in vitro assays and animal models. React4life's technology enhances the reliability and predictivity of various applications, including pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals. The company aims to improve laboratory testing effectiveness while reducing reliance on animal testing, facilitating the cultivation of three-dimensional tissues that closely resemble human tissues for more clinically relevant in vitro experiments.

Matricelf is a biotechnology company focused on advancing tissue engineering and regenerative medicine. Founded in 2019 by Professor Tal Dvir from Tel Aviv University, the company specializes in the 3D printing of tissues and organs, utilizing a proprietary decellularization process that extracts stromal cells and extracellular matrix from small biopsy samples. This process generates a thermo-responsive hydrogel, which is then combined with reprogrammed induced pluripotent stem cells to create functional tissues through a patent-pending methodology. Matricelf is particularly dedicated to developing spinal cord implants for patients with traumatic injuries, aiming to restore neuronal activity and enhance motor functions, thereby improving patients' quality of life and facilitating their reintegration into the community.

EcoPhage is a biotechnology company focused on developing and commercializing bacteriophage-based bactericides designed for sustainable crop protection. The company addresses the significant challenges posed by bacterial infections in agriculture, which contribute to an estimated 10% loss in global food production each year. EcoPhage's innovative products utilize bacteriophages—viruses that specifically target bacteria—to offer nontoxic solutions for preventing and curing bacterial diseases in plants. By leveraging a proprietary technological platform co-developed with the Weizmann Institute of Science, EcoPhage aims to revolutionize the global bactericides market by increasing plant yields, reducing disease-related losses, and promoting environmental sustainability. Unlike conventional pesticides, EcoPhage's solutions provide high specificity and effectiveness with minimal negative impact on the environment, positioning the company as a leader in the transformation of agricultural practices through advanced, eco-friendly technology.

Biomineral Systems is a company focused on environmental biochemical research and technology aimed at addressing global environmental challenges. It offers a range of services, including phosphorus management, soil organic carbon management, and enhancement of soil quality. The company specializes in biogeochemical modeling for forest management, carbon trading and capture, as well as mineral synthesis and characterization. Additionally, Biomineral Systems provides consulting services and environmental policy advice to government agencies and medium to large enterprises. By equipping scientists and engineers with the tools and knowledge necessary to tackle issues related to food security, environmental sustainability, and biodiversity, Biomineral Systems plays a vital role in promoting ecological health and resilience.

mk2 Biotechnologies uses a synthesis process to design, synthesize, and research peptides and proteins. Their process allows the scalable and production of purity peptides and proteins for a range of applications.

KriyaBio is a biotechnology company focused on developing innovative drug delivery solutions utilizing its proprietary permeation enhancer, KB01. This advanced technology serves as a smart tight junction modulator, enhancing the absorption of co-administered therapies. KriyaBio's approach aims to improve patient safety and compliance by offering alternatives to traditional drug delivery methods, such as replacing intravitreal injections of biologics with eye drops. By facilitating more effective delivery of medications, KriyaBio seeks to reduce healthcare costs while enhancing therapeutic outcomes for patients.

OrganoTherapeutics is a company focused on developing medical drugs aimed at treating Parkinson's disease. It utilizes advanced human-specific mini-brain models that accurately replicate the pathology of Parkinson's disease for the discovery and development of effective drug candidates. By employing three-dimensional models derived from both healthy individuals and patients with Parkinson's disease, OrganoTherapeutics identifies the therapeutic potential of various compounds and analyzes data using artificial intelligence. This innovative approach facilitates the screening of new molecules, allowing researchers to advance novel drug candidates. The company has already developed proprietary drug candidates and has access to extensive libraries for further research and development.

Computational Life Inc. is a technology company based in Wilmington, Delaware, focused on developing advanced software for healthcare applications. Founded in 2018, the company specializes in creating a Digital Avatar Platform (DAP) that simulates human and animal physiological systems using validated mathematical models. Its software models various bodily functions, including arterial and venous dynamics, heart activity, microcirculation, pulmonary circulation, cerebrospinal fluid movement, and brain interstitial fluid behavior. The platform aims to enhance medical solutions by predicting personalized patient outcomes in multisystemic diseases, allowing healthcare providers to better manage complex conditions through informed simulations of medical treatments.

Tzofen is a biotechnology company focused on developing a novel biological platform aimed at treating various types of cancer. This innovative platform has demonstrated the ability to eliminate cancer growth both in vitro and in vivo, highlighting its potential to significantly impact cancer treatment. By advancing this technology, Tzofen seeks to contribute to saving millions of lives affected by cancer.

BINK Bio is working on developing biotech alternatives to reduce environmental damage. The company focuses on and technologies in the fields of biotech based dyes.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.

Vyasa Analytics is a technology company that specializes in providing an AI-powered platform tailored for life sciences and healthcare organizations. Its flagship product, Vyasa Layar, facilitates the integration and analysis of diverse data sources across both cloud and on-premise environments. This platform creates a unified data landscape that organizations can explore through a suite of low-code deep learning applications. Vyasa's offerings include advanced features such as dark data analytics, neural concept recognition, and secure cloud deployment, all designed to empower organizations to leverage deep learning for enhanced data insights. By enabling collaborative analytics and project-based deep learning, Vyasa Analytics supports its clients in effectively managing and utilizing their enterprise data.

Onexio Biosystems is a research and development company. They offer HTS screens that typically utilize a single reporter cell type that lacks important confounding biology, including drug metabolism and paracrine and endocrine cell interactions. Their microDUO supports co-culture and multi-culture to improve human relevance in drug discovery and chemical screening.

Amphasys is a technology company that specializes in the development and marketing of innovative, chip-based single-cell analysis technology. Founded in 2012 as a spin-off from Axetris AG, the company focuses on simplifying, accelerating, and miniaturizing complex cell analyses, making them accessible for use outside traditional laboratory settings. The technology, initially developed in collaboration with the Swiss Federal Institute of Technology Lausanne in 2004, has been validated through extensive research with various cell types and is currently employed in applications such as pollen quality monitoring and milk analysis. By eliminating the need for time-consuming and complex sample preparation steps, including cell labeling, Amphasys enables clients to conduct label-free analyses of single-cell characteristics such as size, morphology, viability, and differentiation. The company has received recognition for its innovations, including the prestigious Swiss startup prize awarded by the W.A. de Vigier Foundation in 2013.

Onena Medicines is a biotechnology company focused on developing innovative biological therapies to meet significant clinical needs, particularly in breast cancer and other serious orphan diseases. The company utilizes a proprietary antibody drug discovery platform that leverages advanced artificial intelligence to reprogram cancer cells for the treatment of advanced cancers. This platform enables the design of custom antibodies that exhibit high selectivity and specificity, linked to specialized cellular reprogramming assays. The therapeutic candidates developed by Onena Medicines modulate the activity of a novel class of growth factors known as dual smad inhibiting protein dips, which are implicated in the growth and metastasis of cancer. Through its pioneering approach, Onena Medicines aims to provide physicians with access to groundbreaking drugs in areas where medical needs remain unaddressed.

Convallo Bio is a biotechnology company focused on developing advanced beneficial bacteria aimed at enhancing the wellness of humans, animals, and the environment. By leveraging molecular technology, the company seeks to discover and deliver next-generation probiotics that can improve health outcomes. Convallo Bio's innovative approach positions it to address various wellness challenges through the production of effective microbial solutions.

Aniluxx Biotechnology, Inc. is a biopharmaceutical company focused on developing innovative topical therapeutics for companion animals affected by skin diseases. Founded in 2019 and based in Chapel Hill, North Carolina, the company aims to enhance the health and well-being of pets by creating treatments for conditions such as atopic dermatitis and osteoarthritis. Aniluxx Biotechnology’s approach leverages a pipeline of topically formulated therapeutics based on compounds that have demonstrated safety and efficacy in humans. These therapeutics are designed to be easy to apply and virtually unnoticeable, minimizing the harsh side effects often associated with systemic medicines. Through its commitment to improving animal care, Aniluxx Biotechnology seeks to provide pet owners with effective solutions for managing their pets' health issues.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, specifically targeting perinatal brain injury. Its lead drug candidate promotes the regeneration of myelin-producing oligodendrocytes and aims to reverse white matter injury in premature infants. This therapeutic approach enables healthcare providers to offer treatment to all babies at risk of brain injury, ultimately striving to improve neurodevelopmental outcomes for affected children.

Mantle Biotech is a medical diagnostics company based in Cambridge, Massachusetts, founded in 2019. The company specializes in engineering heat-stable binding proteins that accurately identify disease biomarkers in patient samples. Through a process of directed evolution, Mantle Biotech modifies proteins derived from microbes to develop high-quality diagnostic reagents that are more stable and cost-effective than traditional options. Their innovative approach allows for the adaptation of these reagents to various diseases and testing formats, addressing significant challenges within the broader diagnostic industry. By focusing on unmet needs in global health, Mantle Biotech aims to provide clinics with robust and accurate alternatives to conventional diagnostic methods.

Clara Biotech is a biotechnology company that focuses on the isolation and purification of exosomes from small fluid samples, facilitating liquid biopsy applications for the early detection of diseases such as cancer and Alzheimer's Disease. The company's innovative platform overcomes traditional challenges in exosome harvesting, which typically relies on a lengthy ultra-centrifugation process. Clara Biotech's technology allows for the extraction of pure, viable exosomes from any biofluid source, enhancing the purity and potency of these cellular markers. In addition to advancing diagnostic capabilities, the platform also supports the development of precision medicine by enabling targeted drug delivery directly to specific cells. By bridging the gap between research and patient care, Clara Biotech positions itself at the forefront of exosome-related breakthroughs in the biopharmaceutical field.

InvivoSciences is a biotechnology company focused on enhancing drug discovery and repositioning through innovative phenotypic compound screening services. By leveraging advanced tissue engineering techniques combined with assay automation and sample miniaturization, the company provides a cost-effective and rapid platform for therapeutic discovery. InvivoSciences specializes in developing engineered tissue-based assays that closely replicate the biological functions of living organisms, particularly humans and animals. Additionally, the company employs precision medicine approaches by utilizing patient-derived and gene-edited human samples, along with advanced technologies in cell and tissue handling automation, tissue phenotyping assays, and computational biology. This integrated approach enables clinicians to quickly assess the safety and efficacy of treatments tailored to specific patient populations, improving the drug development process before entering costly clinical trials.

MSL Pharma is a pharma company that performs ideation, analysis and identifies the solutions to treat diseases.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, specifically targeting perinatal brain injury. Its lead drug candidate promotes the regeneration of myelin-producing oligodendrocytes and aims to reverse white matter injury in premature infants. This therapeutic approach enables healthcare providers to offer treatment to all babies at risk of brain injury, ultimately striving to improve neurodevelopmental outcomes for affected children.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

Phylomics Diagnostics is a biotechnology company that specializes in the detection of multiple cancers.

KJ scientific ensures testing and analysis of chemicals product to safety for human and environmental health.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of innovative healthcare devices. The company has created EmbryoSpin, a device that performs microscopic Nuclear Magnetic Resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold. This groundbreaking device is designed to operate at the scale of a single human embryo, providing a robust and user-friendly solution for researchers. EmbryoSpin facilitates non-invasive embryo viability screening for in-vitro fertilization and enhances biochemical research by allowing detailed chemical analysis of microscopic samples. Annaida Technologies' advancements aim to improve outcomes in reproductive health and deepen understanding in various areas of biochemical research.

Fluent BioSciences is a life science technology company focused on single-cell molecular analysis, eliminating the need for complex microfluidic instrumentation. The company’s proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), facilitates the instantaneous self-assembly of individual cells or molecules into millions of uniform partitions. This innovative approach allows for sensitive and unbiased preparation of proteins and nucleic acids, enhancing sequencing applications. By making single-cell and molecular analysis more accessible, Fluent BioSciences enables a broader range of researchers in biotechnology, pharmaceuticals, and academic institutions to conduct advanced analyses, thereby expanding market opportunities within the life sciences field.

Haima Therapeutics is a pre-clinical stage biotechnology company dedicated to developing bio-inspired therapies aimed at treating bleeding and other blood-related disorders. The company is focused on creating platelet-inspired therapeutics that address conditions where platelets are integral to disease progression, including thrombosis, inflammation, and cancer. Utilizing a novel, fully-synthetic nanoparticle-based hemostatic technology, Haima Therapeutics enhances the body's natural clotting mechanisms at the site of injury. This innovation is designed to help patients recover more rapidly from traumatic injuries, surgeries, and various blood-related ailments.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

Gateway Biotechnology is a drug development company focused on creating innovative small molecule therapeutics for individuals with hearing disabilities. The company specializes in developing preclinical animal model systems to facilitate trials for drug candidates targeting conditions such as noise-induced hearing loss and tinnitus. By advancing a pipeline of science-based solutions, Gateway Biotechnology aims to provide new drug development and delivery methods, ensuring that patients receive treatments with proven safety records to effectively address hearing disorders.

CrystalsFirst GmbH is a biotechnology company based in Marburg, Germany, founded in 2018, that specializes in protein crystal stabilization methodologies to enhance drug candidate screening. The company offers innovative technologies, including SmartSoak, which is designed for screening small molecule arrays to identify novel lead candidates, and SmartLib, a compound library for fragment-based drug discovery. Additionally, CrystalsFirst provides SmartRefine, a software solution for the automated refinement of crystallographic diffraction data. Their MAGNET platform integrates high-performance structural biology, computational modeling, and machine learning to address limitations in small molecule drug discovery. By utilizing three-dimensional models and a "crystal structure first" strategy, the company enables the rational design of therapeutic compounds, facilitating rapid access to diverse chemical scaffolds and optimizing lead candidates. CrystalsFirst serves pharmaceutical companies by accelerating the drug discovery process and enhancing the likelihood of finding effective new treatments.

Environmental Quality Operations (EQO) is a company focused on advancing environmental management through innovative molecular biology techniques. Its primary goal is to detect, monitor, and eradicate invasive species using a blend of bioengineering and diagnostic development expertise. EQO's services include highly sensitive assays for early detection of nuisance species, providing detailed analytics on population dynamics and activity. The company has developed a pioneering automated sampling platform that can be deployed at critical sites vulnerable to infestations, allowing for programmable sampling and rapid analysis of results upon submission. In addition to detection and monitoring, EQO conducts research and development aimed at creating targeted biopesticides designed to eliminate invasive species while minimizing adverse effects on native ecosystems, ultimately reducing costs associated with remediation efforts.

NovoThelium is a biotechnology company founded in 2015 by biomedical engineers motivated by personal experiences with breast cancer. The company specializes in developing a tissue-engineered nipple matrix aimed at improving breast reconstruction for cancer survivors. NovoThelium's innovative approach involves a decellularization process that utilizes human donor breast tissue, which has been treated to remove DNA and donor cells while preserving essential proteins and structures. This process allows patients to regenerate a nipple using their own cells, resulting in a natural appearance with appropriate projection, pigmentation, and enhanced sensation. By focusing on nipple regeneration after mastectomy, NovoThelium addresses a significant need for more natural reconstructive options in breast cancer care.

BMSEED is a manufacturer specializing in research tools that replicate stretch-induced neurotrauma in vitro, aimed at advancing the understanding of injury processes and therapeutic options in both academic and pharmaceutical settings. The company's innovative neurotrauma model allows for a direct comparison of the electrophysiological activity of healthy cells before injury and damaged cells after injury, thereby enhancing the evaluation of neuroprotective treatments. Additionally, BMSEED develops sustainable elastic electronic devices that incorporate stretchable gold films, facilitating their integration with biological systems such as cells, tissues, or skin. These devices are designed to improve interactions during traumatic brain injury surgeries, offering healthcare providers better data for therapeutic, diagnostic, and research purposes.

Scintia is a manufacturer specializing in laboratory equipment and educational kits designed to facilitate learning and research in synthetic biology. Their primary products are genetic engineering educational kits, which include all necessary materials and teaching guides, allowing users to conduct practical biological reactions. The company aims to overcome barriers hindering biotechnology development by providing accessible tools for education and innovation.

Simbiótica Labs specializes in developing biological technology solutions aimed at enhancing crop productivity. The company focuses on creating organic products that optimize nutrient absorption in plants while ensuring environmental sustainability. By revitalizing the root ecosystem and fostering synergy among microorganisms, Simbiótica Labs enables its clients to improve crop yields effectively. Its innovative approach seeks to balance agricultural productivity with ecological health, positioning the company as a leader in sustainable agricultural practices.

LIfT BioSciences is a biotechnology company based in London, established in 2016, that specializes in advanced innate immuno-cell therapies. It has developed a unique platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT), which enables the production of Immunomodulatory Alpha Neutrophils (IMANs) from induced pluripotent stem cells (iPSCs). This technology aims to address the limitations of existing therapies for solid tumors by utilizing CAR neutrophil cell therapy. The IMANs can alter the tumor microenvironment, enhancing the immune response and enabling a more effective attack on tumors. By leveraging proprietary enhancement media and genetic engineering, LIfT BioSciences seeks to significantly increase the cancer-fighting capabilities of these cells, offering patients the potential for improved outcomes and lasting immunity against cancer.

Nagi Bioscience SA is a Swiss company based in Lausanne that specializes in developing and manufacturing an innovative automated testing device utilizing organism-on-chip technology. This device leverages the microscopic worm Caenorhabditis elegans for in vivo testing, enabling pharmaceutical, chemical, and cosmetic companies to assess the toxic and beneficial effects of various substances. By integrating fully automated in vitro handling, culture, and analysis, Nagi Bioscience's platform facilitates toxicity testing, drug discovery, and anthelmintic testing. This approach allows clients to evaluate comprehensive biological responses that can only be observed at the level of the whole organism, thereby transforming traditional testing methodologies.

Cellular Preservation Technologies is a biotechnology company specializing in the preservation of biological cells and tissues through innovative techniques involving hyperbaric xenon gas and refrigeration. Their advanced technology significantly enhances the durability of platelets, leading to increased availability and a reduction in waste, while also minimizing the risk of bacterial infections. By improving the preservation process, the company enables hospitals and blood banks to deliver more effective and timely therapeutic services to patients, thereby enhancing overall healthcare outcomes.

Neurescence Inc. is a biotechnology company based in Toronto, Canada, focused on developing assessment tools for brain diseases and effective therapeutics. Established in 2014, the company specializes in biological optical imaging, offering innovative products such as its Quartet, a miniature fluorescence microscope designed for neuronal calcium imaging. This device allows for the simultaneous monitoring of neuronal activity across multiple regions of the brain and spinal cord in freely behaving subjects. Neurescence also provides GRIN lenses that facilitate imaging by transmitting fluorescence signals from neurons to a CMOS sensor, enabling healthcare providers to gain insights into brain function and localize areas for potential intervention in conditions such as Alzheimer's, epilepsy, and depression.

Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.

ReviveMed Inc is a precision-medicine company based in Cambridge, Massachusetts, founded in 2016. The company specializes in a platform that utilizes data from small molecules, or metabolites, applying a network-based machine learning algorithm to conduct integrative analyses of untargeted metabolomic data alongside other extensive molecular information, such as data from genes, proteins, drugs, and diseases. This innovative approach transforms metabolomic data into actionable insights, facilitating the development of in-house therapeutics tailored for patients suffering from liver diseases and related conditions. ReviveMed aims to enhance health outcomes by unlocking the potential of metabolomics in medical research and treatment.

Halo Life Science is a company dedicated to enhancing human health and wellness through innovative nutritional solutions. After three years of research and development, the company has introduced Naturalin™, a patent-pending phytonutrient designed to improve the nutritional value of everyday foods and beverages. This multifunctional bioactive is also available in various nutritional supplement formats, making it suitable for addressing chronic conditions, illnesses, and obesity. Supported by research from the Dell Pediatric Research Institute at The University of Texas at Austin, Naturalin™ has been validated for safety and efficacy. Halo Life Science's mission is to provide safe, effective, and accessible food and nutritional products to consumers, ensuring that enhanced nutrition is available to everyone, everywhere.

Bezoar Laboratories is focused on enhancing the health of humans, animals, and the environment through innovative microbial solutions. The company develops probiotic medical and pharmaceutical products designed to alleviate gastrointestinal issues, particularly those related to methane gas production. Its offerings are formulated to be free of gluten and dairy, while maintaining low acidity levels. This formulation aims to provide customers with relief from symptoms such as bloating, constipation, and diarrhea. Bezoar Laboratories is committed to creating effective solutions that promote overall well-being.

Octagon Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibiotic medicines for life-threatening autoimmune diseases such as Pemphigus Vulgaris, Systemic Lupus, and Multiple Sclerosis. Established in 2016, the company aims to address multi-drug resistant infections and has demonstrated effectiveness against critical pathogens identified by the World Health Organization. Octagon specializes in creating targeted immunomodulator therapies designed to reset immune homeostasis in patients suffering from chronic autoimmune and inflammatory conditions. By subtly altering the metabolic processes in immune cells during disease, Octagon's medicines aim to selectively target dysregulated immune cells, thus allowing patients to potentially avoid chronic immunosuppression. The company is housed in the Pagliuca Life Lab, adjacent to Harvard University, which facilitates the rapid development of its critical therapies with minimal overhead. With a management team of skilled scientists, clinicians, and entrepreneurs, Octagon Therapeutics is committed to leveraging extensive research experience in drug development to advance its therapeutic innovations.

MobioSense is engaged in the development of advanced diagnostic solutions for heart disease. The company's flagship product, HERO, is a portable, high-sensitivity troponin test that enables rapid diagnosis of heart attacks. Unlike conventional tests that require multiple samples over an extended period, HERO can provide results in just three hours, facilitating immediate decision-making in both hospital and ambulance settings. This innovation not only improves patient care by allowing for timely interventions but also helps alleviate emergency room congestion by directing patients to the appropriate care pathways. In addition to its heart disease monitoring capabilities, MobioSense is also involved in creating detection reagents for diseases such as African Swine Fever and COVID-19, further enhancing its commitment to healthcare advancements.

Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.

Reminisciences develops a symbiotic treatment and a companion diagnostic for Alzheimer's disease through targeting the gut microbiome. Reminisciences exploits the crucial role of gut microbiota in human physiology and more specifically as we have discovered in Alzheimer's disease. There is no effective treatment for Alzheimer, despite 51 million patients in need. Our company develops 2 products: CerebralX, a symbiotic therapeutic treatment to restore altered gut microbiota and stop or delay Alzheimer's disease, and ReminiTest, a diagnostic based upon microbiota profiling.

Dicronis GmbH, founded in 2018 and based in Monteggio, Switzerland, specializes in the development of innovative microneedle technology for diagnostic and therapeutic applications. The company's flagship product, Lymphit, is a wearable device designed to monitor lymphatic function in a safe and scalable manner from the patient's home. This device allows for the early diagnosis of secondary lymphedema, a significant complication that can arise from cancer treatments. By utilizing a wearable patch that applies a fluorescent substance to the skin, Lymphit measures its uptake into lymph vessels through a portable detector. This real-time monitoring enables healthcare providers to diagnose lymphedema before symptoms develop and to tailor conservative treatment strategies effectively. As a result, Dicronis aims to improve patient outcomes and quality of life while also generating cost savings for the healthcare system.

NerveSolutions is a biomedical technology company focused on creating advanced implantable nerve interface devices. The company has developed a surgical device that aims to prevent the formation of neuromas following amputation or nerve injury. This bioengineered device is designed to be placed on the cut ends of nerves, effectively inhibiting the development of painful neuromas. By doing so, NerveSolutions enables surgeons to deliver optimal care to patients with peripheral nerve injuries, helping them regain functionality through innovative treatment options.

Nanosynex is a diagnostic test that checks bacterial resistance to antibiotics in a record time, using a phenotypic approach that involves microfluidic techniques and fluorescent-based analysis. The test helps doctors determine faster (same-day results) the most appropriate antibiotic treatment for their patients, helping them recover in a shorter time and preventing the spread of resistant bacteria in the environment. By limiting prolonged hospitalization, Nanosynex allows to save significant healthcare costs.

General Biotechnologies identifies and develops undervalued discoveries in the life sciences. Their flagship program — Nivien Therapeutics — is a venture-backed oncology startup spun out of Harvard Medical School.

Structured Immunity is a protein engineering company focused on enhancing the safety and effectiveness of T cell receptor-based therapies. Founded in 2017 by David Hardwicke and Timothy Riley, the company leverages over 20 years of research from the laboratory of Brian Baker to develop advanced techniques for optimizing T cell receptors. By increasing the target specificity of these receptors, Structured Immunity aims to improve drug efficacy while minimizing potential side effects associated with T cell therapies. The company specializes in enhancing the human immune system for cell-based cancer immunotherapy, providing pharmaceutical firms with innovative solutions for engineering patentable cellular cancer therapies with improved tumor targeting capabilities.

GliaPharm SA is a Swiss biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders. Established in 2016 and headquartered in Geneva, GliaPharm specializes in targeting glial cells, which are the support cells of neurons, to enhance brain metabolism in pathological conditions. The company utilizes its GliaX technology platform to identify drugs that influence glial cell activity and brain energy metabolism. This platform incorporates high throughput screening technologies, metabolic tests for in vitro and in vivo assessments, and various rodent models to study neurological diseases such as Alzheimer's disease, amyotrophic lateral sclerosis, and other psychiatric conditions. Through its research and development efforts, GliaPharm aims to provide healthcare providers with novel therapeutic options for patients suffering from these disorders, positioning itself as a leader in glia-mediated neuroprotection and cognitive function maintenance.

Torigen Pharmaceuticals is a company dedicated to advancing cancer care solutions for companion animals. Founded in 2013 by Ashley Kalinauskas and Mark Suckow, the company is based in Farmington, Connecticut. Torigen focuses on developing innovative immunotherapy treatments, including an experimental autologous cancer vaccine that activates the immune system to target specific tumor-associated antigens on cancer cells. This approach aims to enable veterinarians to detect and treat cancer in animals more effectively, reducing the reliance on invasive surgeries and chemotherapy. By leveraging existing scientific research, Torigen seeks to improve outcomes for pets diagnosed with cancer, enhancing their quality of life through novel therapeutic strategies.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Hive is a crowdsourcing platform for biomedical PhDs ​

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

Cellino is focused on developing a scalable, automated biomanufacturing system aimed at producing personalized cell therapies. The company's innovative platform leverages AI-guided laser editing to generate autologous induced pluripotent stem cells (iPSCs) efficiently and at scale. By utilizing image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to make advanced, potentially curative treatments accessible for a range of chronic degenerative diseases, including vision loss and Parkinson's disease. The company's mission is to transform healthcare by enabling personalized therapies that can significantly improve patient outcomes and overall health.

ReviveMed Inc is a precision-medicine company based in Cambridge, Massachusetts, founded in 2016. The company specializes in a platform that utilizes data from small molecules, or metabolites, applying a network-based machine learning algorithm to conduct integrative analyses of untargeted metabolomic data alongside other extensive molecular information, such as data from genes, proteins, drugs, and diseases. This innovative approach transforms metabolomic data into actionable insights, facilitating the development of in-house therapeutics tailored for patients suffering from liver diseases and related conditions. ReviveMed aims to enhance health outcomes by unlocking the potential of metabolomics in medical research and treatment.

Octagon Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibiotic medicines for life-threatening autoimmune diseases such as Pemphigus Vulgaris, Systemic Lupus, and Multiple Sclerosis. Established in 2016, the company aims to address multi-drug resistant infections and has demonstrated effectiveness against critical pathogens identified by the World Health Organization. Octagon specializes in creating targeted immunomodulator therapies designed to reset immune homeostasis in patients suffering from chronic autoimmune and inflammatory conditions. By subtly altering the metabolic processes in immune cells during disease, Octagon's medicines aim to selectively target dysregulated immune cells, thus allowing patients to potentially avoid chronic immunosuppression. The company is housed in the Pagliuca Life Lab, adjacent to Harvard University, which facilitates the rapid development of its critical therapies with minimal overhead. With a management team of skilled scientists, clinicians, and entrepreneurs, Octagon Therapeutics is committed to leveraging extensive research experience in drug development to advance its therapeutic innovations.

LYF Rescue Drone specializes in developing an innovative search and rescue system aimed at finding avalanche victims more efficiently than traditional methods. The company addresses the critical issue that approximately 150 ski freeriders die annually due to avalanches, with current technologies like avalanche victim detectors (AVDs) often being slow and user-dependent. LYF Rescue Drone's solution involves a portable drone system designed to autonomously locate buried victims by reducing human error and search time. This technology enhances the chances of survival for those caught in avalanches by quickly identifying their location and alerting rescue teams.

UrSure, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing and commercializing diagnostic tests that enhance medication adherence. Founded in 2015, UrSure specializes in patient-friendly urine and blood test kits designed to measure adherence to HIV medications, including pre-exposure prophylaxis (PrEP). By providing these diagnostic tools, UrSure aims to improve health outcomes for individuals undergoing treatment and prevention for HIV, thereby addressing a critical need in the management of the disease.

eggXYt is a biotechnology company focused on the early sex detection of chick embryos immediately after eggs are laid. The company has developed a non-invasive gene-editing technology that utilizes clustered regularly interspaced short palindromic repeats to add a genetic marker to the eggs. This marker causes male eggs to emit a glow when scanned, allowing poultry farms to identify and incubate only female eggs. By enabling early identification, eggXYt's technology helps to streamline operations, reducing waste associated with the incubation of male chicks, which are typically culled after identification. This innovative approach not only enhances efficiency in poultry production but also supports sustainability within the food industry.